Cardio-Oncology

Table 2 Demographic and clinical characteristics of 95 eligible patients

From: Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Characteristic	Patients n(%)^c	Missing n(%)
Gender^a
Male	55 (57.9)
Female	40 (42.1)
Age, years^b	65.0 (27–87)
IPI^a
0–2	62 (66.7)	2 (2.1)
3–5	31 (33.3)
B-symtoms^a
Yes	32 (33.7)
No	63 (66.3)
DXR dose mg/m^{2 b}	292.6 (49.1–348.5)^d	6 (6.3)
Smoking^a
Never	39 (52.7)	21 (22.1)
Former	24 (32.4)
Current	11 (14.9)
BMI^b	25.0 (17.5–52.1)	4 (4.2)
eGFR^a
0–1	74 (82.2)	5 (5.3)
2–4	16 (17.8)
CRP^a
Normal	32 (34.8)	3 (3.2)
Elevated	60 (65.2)
Comorbidity^a
Heart disease	21 (22.6)	2 (2.1)
Vascular disease	10 (10.8)	2 (2.1)
Hypertension	34 (36.6)	2 (2.1)
DM `	13 (14.0)	2 (2.1)
Medication^a
Metformin	9 (9.8)	2 (2.1)
Beta-blocker	18 (19.4)	2 (2.1)
ACE or ARB	26 (28.0)	2 (2.1)
Statins	23 (24.7)	2 (2.1)

Data are presented as ^an (%) or ^bmedian (range). IPI, international prognostic index; DXR, doxorubicin; BMI, body mass index; eGFR, estimated glomerular filtration rate; CRP, c reactive protein; DM, diabetes mellitus; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker. ^c Fever/night sweat/weight loss. ^c %; number of patients with X divided with total number of cases with X known. Missing cases are excluded, ^dMedian dose for 82 patients.7 patients recieved no DXR. 6 patients where dose/m2 is missing

Back to article page

ISSN: 2057-3804

Contact us

General enquiries: journalsubmissions@springernature.com